Full video transcriptClick to expand
Auto-generated transcript of @daisyfamhealth's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00AOD-9604. One of the most talked about peptides in the weight management world.
- 0:08And for the reason, it was originally developed as a modified fragment of human growth hormone,
- 0:15but without the part that affects the growth or the blood sugar.
- 0:18Research has isolated the portion responsible for fat metabolism and turn it into its own peptide.
- 0:26What makes AOD-9604 interested, trusting is how it targeted that it is.
- 0:32Instead of acting like a traditional growth hormone, it appears to focus specifically on lipolysis,
- 0:39the breakdown of store fats.
- 0:41While also slowing down lipogenesis, which is the formation of new fat cells,
- 0:46that's a powerful combination for people working in metabolic health, like me.
- 0:52People often describe it as an assistant rather than a driver.
- 0:56It doesn't override poor habits, but it can support the body's fat burner pathways
- 1:02when paired with movement, teen, hydration, and consistent nutrition.
- 1:08Some providers use it alongside other protocols like the GOP's, which is what I do,
- 1:15or metabolic peptides, because it tends to play nicely with the others.
- 1:19There is published research on AOD-9604, including human studies,
- 1:25but like most peptides, the data is still evolving.
- 1:29What we can say is that it has been explorable obesity, carlage replayer, carlage repair,
- 1:37and inflammation with a surprisingly safe profile so far.
- 1:42As always, peptides are tools, not shortcuts, and education helps people use them wisely.
- 1:49As a disclaimer, this content is for educational purposes only,
- 1:53and not intended to diagnose, treat, or cure any condition.
- 1:57Always going to sort of qualify a health care professional.
- 2:01And if you don't know who I am, my name is Ang Nurse Practitioner,
- 2:05and I love peptides. I love functional medicine. I love integrative health.
- 2:10And so I'm always looking for ways to step outside the box to help you, help your body, help itself.
- 2:18Until next time.
AOD9604 and fat loss: what the evidence actually shows
Quick answer
AOD-9604 is a synthetic peptide fragment of human growth hormone (residues 176-191) studied primarily for its lipolytic properties in preclinical models and early-phase human trials, with Phase III obesity trials failing to meet primary endpoints. The creator accurately describes its mechanism but presents animal and early human data as more conclusive than the published record supports. Pairing it with GLP-1 receptor agonists, as she mentions doing clinically, has no published safety or efficacy data to date.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For AOD9604 and fat loss: what the evidence actually shows, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Supports SELECT-context pages where semaglutide claims touch long-term weight change and cardiovascular-risk populations.
PubMed
Semaglutide for cardiovascular event reduction in people with overweight or obesity
Baseline SELECT source for cardiovascular-outcomes framing in people with overweight or obesity.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
AOD9604 and fat loss: what the evidence actually shows is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "AOD9604 and fat loss: what the evidence actually shows" from Daisy Direct Primary Care. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: AOD-9604 is a synthetic peptide fragment of human growth hormone (residues 176-191) studied primarily for its lipolytic properties in preclinical models and early-phase human trials, with Phase III obesity trials failing to meet primary endpoints.
The reason this review is not generic is the source wording and the canonical claim label "peptides let s chat about aod9604 it is strictly for burning fat aod." In this clip, the useful excerpt is: "AOD-9604." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
AOD-9604 is a synthetic peptide fragment of human growth hormone (residues 176-191) studied primarily for its lipolytic properties in preclinical models and early-phase human trials, with Phase III obesity trials failing to meet primary endpoints.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- AOD-9604 is a synthetic peptide fragment of human growth hormone (residues 176-191) studied primarily for its lipolytic properties in preclinical models and early-phase human trials, with Phase III obesity trials failing to meet primary endpoints. The creator accurately describes its mechanism but presents animal and early human data as more conclusive than the published record supports. Pairing it with GLP-1 receptor agonists, as she mentions doing clinically, has no published safety or efficacy data to date.
- AOD-9604 is not FDA-approved for any medical use; its 2014 FDA GRAS designation applies only to its use as a food ingredient, not as a therapeutic drug.
- Phase III clinical trials conducted by Metabolic Pharmaceuticals failed to show statistically significant weight loss over placebo, a fact absent from this video.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- AOD-9604 is not FDA-approved for any medical use; its 2014 FDA GRAS designation applies only to its use as a food ingredient, not as a therapeutic drug.
- Phase III clinical trials conducted by Metabolic Pharmaceuticals failed to show statistically significant weight loss over placebo, a fact absent from this video.
- Heffernan et al. (2001, American Journal of Physiology) confirmed lipolytic and anti-lipogenic effects in rodent models, which is the strongest mechanistic evidence cited in support of this peptide.
- Preclinical cartilage repair data exists (Ghosh et al., 2007) but no peer-reviewed human trials have confirmed this as a clinical benefit.
- Zero published studies exist on combining AOD-9604 with GLP-1 receptor agonists; the claim that they 'play nicely' is based on clinical anecdote, not data.
- In the US, AOD-9604 is dispensed through compounding pharmacies as an unapproved drug; sourcing, sterility standards, and dosing accuracy vary by pharmacy and are not federally regulated the way approved drugs are.
- Safe and effective are not the same thing. The peptide's clean safety record in trials does not mean it produces meaningful fat loss in humans at available doses.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @daisyfamhealth actually say?
In short: AOD-9604 is a modified fragment of human growth hormone engineered to target fat metabolism without affecting blood sugar or growth. The creator, a nurse practitioner, describes it as supporting "fat burner pathways" when paired with lifestyle habits, and notes it has been studied for obesity, cartilage repair, and inflammation. She also mentions pairing it with GLP-1 protocols in her own practice.
A few specific claims stand out. She says it promotes lipolysis (fat breakdown) while slowing lipogenesis (new fat cell formation), calling that "a powerful combination." She acknowledges the data is "still evolving" and wraps with a standard educational disclaimer. The framing is generally measured, though the caption calling it "strictly for burning fat" is a bit more aggressive than the nuanced language in the actual video.
Does the science back this up?
Partially, yes, but the evidence base is thinner than the peptide's reputation suggests. The most significant published work comes from Metabolic Pharmaceuticals, the Australian company that developed AOD-9604 and ran it through Phase I, II, and III trials in the early 2000s. Those trials showed modest weight loss results and a clean safety profile, but the Phase III trials failed to demonstrate statistically significant weight loss over placebo at the doses tested.
The lipolysis claim has legitimate preclinical support. Heffernan et al. (2001, American Journal of Physiology) showed AOD-9604 stimulated lipolysis and inhibited lipogenesis in rodent fat cells, which is exactly what the creator describes. Whether those mechanisms translate cleanly to meaningful fat loss in humans at practical doses is a different and unresolved question. The cartilage repair angle has some preclinical backing (Ghosh et al., 2007, Osteoarthritis and Cartilage) but calling it an established benefit stretches the data considerably.
What did they get wrong (or right)?
Credit where it is due: the mechanistic explanation is accurate. AOD-9604 is a C-terminal fragment of human growth hormone (hGH 176-191) modified with a disulfide bridge, and the design rationale, removing the IGF-1-stimulating domain while preserving the lipolytic region, is described correctly. Saying it does not affect blood sugar is also consistent with the published safety data.
Where she overstates things: describing existing research as showing it has been studied for obesity "with a surprisingly safe profile so far" glosses over the fact that Phase III obesity trials failed their primary endpoints. Safe is not the same as effective. The lipogenesis inhibition claim is real in cell and animal models, but she presents it as an established human effect, which it is not. The caption "strictly for burning fat" is also flatly reductive given the actual complexity and limitations of the data. And the offhand mention of stacking with GLP-1s, while framed as personal practice, is not supported by any published combination safety or efficacy data.
What should you actually know?
AOD-9604 is not FDA-approved for any indication. It received FDA GRAS (Generally Recognized as Safe) status as a food ingredient in 2014, which is sometimes misrepresented as a broader regulatory endorsement. It is not. In the United States, it is currently available primarily through compounding pharmacies as an unapproved drug, and its regulatory status is actively shifting.
- The human trial data for weight loss is limited and the Phase III results were not positive enough to earn approval.
- Preclinical fat metabolism data is real but animal-to-human translation in peptide research is notoriously inconsistent.
- There is no peer-reviewed human data on combining AOD-9604 with GLP-1 receptor agonists. Stacking two agents that affect metabolic pathways without that data is a clinical unknown, not an established protocol.
- Anyone considering this peptide should be working with a licensed provider who can document informed consent, monitor for adverse effects, and source from a verified compounding pharmacy following USP <797> standards.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Daisy Direct Primary Care · TikTok creator
7.1K views on this video
Let’s chat about AOD9604, it is strictly for burning fat 🔥 #aod #aod9604 #peppers #daisyfamilyhealth #arizona
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about aod-9604?
AOD-9604 is not FDA-approved for any medical use; its 2014 FDA GRAS designation applies only to its use as a food ingredient, not as a therapeutic drug.
What does the video say about phase iii clinical trials conducted by metabolic pharmaceuticals failed to?
Phase III clinical trials conducted by Metabolic Pharmaceuticals failed to show statistically significant weight loss over placebo, a fact absent from this video.
What does the video say about heffernan et al. (2001, american journal of physiology) confirmed lipolytic?
Heffernan et al. (2001, American Journal of Physiology) confirmed lipolytic and anti-lipogenic effects in rodent models, which is the strongest mechanistic evidence cited in support of this peptide.
What does the video say about preclinical cartilage repair data exists (ghosh et al., 2007)?
Preclinical cartilage repair data exists (Ghosh et al., 2007) but no peer-reviewed human trials have confirmed this as a clinical benefit.
What does the video say about zero published studies exist on combining aod-9604 with glp-1 receptor?
Zero published studies exist on combining AOD-9604 with GLP-1 receptor agonists; the claim that they 'play nicely' is based on clinical anecdote, not data.
What does the video say about in the us, aod-9604?
In the US, AOD-9604 is dispensed through compounding pharmacies as an unapproved drug; sourcing, sterility standards, and dosing accuracy vary by pharmacy and are not federally regulated the way approved drugs are.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Daisy Direct Primary Care, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.